Epidermolysis Bullosa, also colloquially known as butterfly skin disease, a rare genetic condition that makes your skin very ...

The biotech has quickly turned a cell therapy approval into one of the more lucrative recent sales for a priority review ...

Spring has been bountiful at Cleveland's Abeona Therapeutics. | As Abeona gears up for the commercial rollout of Zevaskyn, ...

It’s so special to be playing for a purpose, the purpose being this incredible mission,” Eddie Vedder tells TODAY.com.

New research reveals the potential of drugs that have been on the market for decades to treat diseases other than those for ...

A Mayo woman who suffers from a rare, genetic skin disease will abseil from the roof of Croke Park to fundraise for a charity ...

In this week’s edition of The Prototype, we look at quantum computing for image recognition, a gene therapy using a patient’s ...

Abeona’s deal value is in line with recent voucher sale transactions amid uncertain times in rare disease drug development.

Abeona's Zevaskyn secures timely FDA nod, priced at $3.1 million, with 2025 sales now forecast at $31.6 million and peak U.S.

The Marketing Authorization Application (MAA) for Day One Biopharmaceuticals and Ipsen’s tovorafenib was accepted for review ...